

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-98. (Canceled)

99. (Previously presented) A method for treating an autoimmune disease in a subject, consisting of administering to the subject a therapeutically effective amount of a composition consisting of one or more humanized, monoclonal anti-IFN- α antibodies or antigen-binding fragments thereof and a diluent, a preservative, a solubilizer, an emulsifier, an adjuvant, a carrier, a buffer, a pharmaceutical additive, a detergent, an anti-oxidant, a bulking substance, a tonicity modifier, a flavoring agent, a lubricant, a suspending agent, a filler, a glidant, a compression aid, a binder, a tablet-disintegrating agent, an encapsulating material, a sweetener, a thickening agent, a color, a viscosity regulator, a stabilizer, an osmo-regulator, a pharmaceutically acceptable propellant, a flavorant, a dye, a coating, or a combination of any thereof, wherein said autoimmune disease is not rheumatoid arthritis, Acquired Immune Deficiency Syndrome (AIDS), or diabetes.

100. (Previously presented) The method of claim 99, wherein the autoimmune disease is selected from the group consisting of ankylosing spondylitis, psoriatic arthritis, aplastic anemia, Behcet's disease, graft-versus-host disease, Graves' disease, hemolytic anemia, hypogammaglobulinemia, hyper IgE syndrome, idiopathic thrombocytopenia purpura (ITP), multiple sclerosis (MS), Myasthenia gravis, psoriasis, lupus and any combination thereof.

101. (Previously presented) The method of claim 99, wherein the autoimmune disease comprises systemic lupus erythematosus (SLE), drug-induced lupus, or a combination thereof.

102. (Previously presented) The method of claim 99, wherein the autoimmune disease is SLE.

103. (New) The method of claim 99, wherein the autoimmune disease is not ankylosing spondylitis.